Free Trial
→ Free Ticker: Anthropic's silent partner could soar after record $2 trillion IPO (From Monument Traders Alliance) (Ad)tc pixel
NASDAQ:NRIX

Nurix Therapeutics Q3 2026 Earnings Date & Estimates

Nurix Therapeutics logo
$22.35 0.00 (0.00%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$22.55 +0.20 (+0.89%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nurix Therapeutics is expected to report Q3 2026 earnings on Monday, October 12, 2026, after market closes.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Nurix Therapeutics in Q3 2026

Nurix Therapeutics is expected to post earnings of -$0.6009 per share on revenue of $24.35 million. In the same quarter a year earlier Nurix Therapeutics reported -$1.03 per share on revenue of $7.89 million. Nurix Therapeutics last reported on July 9, 2026, posting -$0.81 per share and missing the -$0.73 consensus estimate. Nurix Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.6009
Expected Revenue
$24.35 million
Prior-Year EPS
-$1.03
Prior-Year Revenue
$7.89 million
Expected Revenue Growth
+208.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.81 (Missed by -$0.08)
Last Quarter Revenue
$9.04 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Nurix Therapeutics Q3 2026 Earnings FAQ

Nurix Therapeutics (NASDAQ:NRIX) is estimated to report Q3 2026 earnings on Monday, October 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Nurix Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, October 22, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Nurix Therapeutics to post earnings of -$0.6009 per share for Q3 2026.

The consensus revenue estimate for Nurix Therapeutics is $24.35 million for Q3 2026.

Nurix Therapeutics Earnings Headlines

Nurix Initiates Phase 1b/2 Bexobrutideg Trial In Lymphocytic Leukemia
October 7, 2026  |  rttnews.comhttps://www.rttnews.com/3697118/nurix-initiates-phase-1b-2-bexobrutideg-trial-in-lymphocytic-leukemia.aspx
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
October 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376179/0/en/nurix-therapeutics-announces-first-patient-enrolled-in-phase-1b-2-combination-study-of-bexobrutideg-in-chronic-lymphocytic-leukemia.html
Palantir and Wall Street are in on it…
Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has poured billions into this firm, which may have found a solution to the growing AI energy crunch. Unlike pricey chipmakers trading at 40 times earnings, this pure-play AI energy name remains cheap and profitable. See the name and ticker behind this fast-moving story before wider attention catches on.tc pixel
 |  Monument Traders Alliance (Ad)
Nurix Therapeutics, Gilead Sciences Agree on Two-Year Research Term Extension for Oncology Program
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nurix-therapeutics-gilead-sciences-agree-114331310.html
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
October 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374392/0/en/nurix-therapeutics-announces-second-research-term-extension-for-oncology-program-under-collaboration-with-gilead-sciences.html
Nurix Therapeutics (NRIX) Set to Release Quarterly Earnings on Thursday
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31071872
See More Nurix Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nurix Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your email.

About Nurix Therapeutics

Nurix Therapeutics (NASDAQ:NRIX) is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology. The company has also developed immune-modulating programs, including therapies intended to activate antitumor immune responses.

Founded in 2009, Nurix has advanced its programs through research collaborations and strategic partnerships, including a collaboration with Sanofi focused on targeted protein degradation. The company conducts research and clinical development in the United States and works with international partners and clinical sites as its programs progress. Nurix’s common stock trades on the Nasdaq under the symbol NRIX.

View Nurix Therapeutics Profile
Earnings Tools